Max Robotics — Global Service Robot Directory + US Certification

About

Tsunekazu Mizushima is a leading colorectal surgeon and researcher whose work focuses on improving outcomes for rectal cancer patients through innovative surgical techniques and perioperative management. His major contributions span three critical areas: optimizing neoadjuvant therapy, advancing minimally invasive surgery, and predicting postoperative quality of life. Notably, his 2024 meta-analysis demonstrated that robotic surgery significantly reduces the risk of positive circumferential resection margins compared to conventional laparoscopic surgery—a finding with direct implications for oncologic safety. His 2022 case report on total neoadjuvant therapy combined with nivolumab for locally advanced rectal cancer, though early-stage, has already garnered 11 citations, highlighting growing interest in immunotherapy integration. Mizushima also developed and validated the first Japanese prediction model for low anterior resection syndrome (LARS), a debilitating complication affecting bowel function after sphincter-preserving surgery. This model, with 7 citations, enables personalized risk assessment and preoperative counseling. His work bridges technical innovation and patient-centered outcomes, earning him recognition as a key figure in modern rectal cancer care.